Condition
NSCLC, Stage IIIC
Total Trials
5
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Terminated2
Active Not Recruiting2
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT04027647Phase 2Active Not Recruiting
Phase 2 Study of Dacomitinib in NSCLC
NCT05816499Phase 1Active Not Recruiting
Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06374160Not ApplicableNot Yet Recruiting
Exercise in Patients With Advanced Non-small Cell Lung Cancer
NCT04676386Terminated
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
NCT03805841Phase 2Terminated
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Showing all 5 trials